BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24565406)

  • 1. JAK3 inhibition: what potential for the future?
    Legendre C
    Transplant Res; 2013 Nov; 2(Suppl 1):S6. PubMed ID: 24565406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates.
    Borie DC; Larson MJ; Flores MG; Campbell A; Rousvoal G; Zhang S; Higgins JP; Ball DJ; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Changelian PS
    Transplantation; 2005 Dec; 80(12):1756-64. PubMed ID: 16378072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of basiliximab with mycophenolate mofetil in kidney transplantation.
    Baron PW; Weissman J; Ojogho ON; Sahney S; Cutler D; James S; Oculam C; Abdelhalim F; Nehlsen-Cannarella SL; Teichman S; Concepcion W
    Transplant Proc; 2003 Dec; 35(8):2881-4. PubMed ID: 14697927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
    Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G
    Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
    Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
    Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation: A Reappraisal.
    Baan CC; Kannegieter NM; Felipe CR; Tedesco Silva H
    Transplantation; 2016 Sep; 100(9):1833-9. PubMed ID: 27163538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive Management of Pediatric Kidney Transplant Recipients.
    Seeman T
    Curr Pharm Des; 2020; 26(28):3451-3459. PubMed ID: 32640952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial immunosuppression with or without basiliximab: a comparative study.
    Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
    Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Factors of Acute Rejection in Low Immunologic Risk Kidney Transplant Recipients Receiving Basiliximab.
    Pereira M; Guerra J; Neves M; Gonçalves J; Santana A; Nascimento C; da Costa AG
    Transplant Proc; 2016 Sep; 48(7):2280-2283. PubMed ID: 27742279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.
    Flechner SM; Goldfarb D; Modlin C; Feng J; Krishnamurthi V; Mastroianni B; Savas K; Cook DJ; Novick AC
    Transplantation; 2002 Oct; 74(8):1070-6. PubMed ID: 12438948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.